Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan writes that US biotech companies are holding ...
July 11, 2026 06:00 AM EDT
Weekly
Deals, deals, deals; Biohaven takes on Eli Lilly; and more
Max Gelman
Nicole DeFeudis
A $10B deal, China trial scrutiny and highlights from ADA 2026
Roche ends Huntington's gene-silencing programs
Four major biotech updates to catch up on
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials
Welcome back to another edition of Endpoints Weekly! We hope you all have been staying safe indoors as the Canadian wildfires…
Welcome back to Endpoints Weekly! We’re gearing up for a busy week of earnings coverage, as Moderna, AstraZeneca, GSK, Bristol…
US biotechs turn tight-lipped on gene targets and pipelines as China's fast-follower threat intensifies, 20+ founders and…
Welcome back to Endpoints Weekly! This week, we opened nominations for our eighth annual Women in Biopharma report. We’re looking…
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer…
